Stroke Trials Registry

CGS 19755
Selfotel®

Action
Glutamate antagonist (competitive NMDA receptor blocker)

Status
Two phase III multicenter studies of selfotel (ASSIST) abandoned after interim analysis showed no benefit, 1997.

Trial(s)
= Ongoing
= Completed

ASSIST Acute Stroke Studies Involving Selfotel Treatment

Safety and Tolerability of the Glutamate Antagonist CGS 19755 (Selfotel) in Patients With Acute Ischemic Stroke

Web Links and Publications

Norvatis Pharmaceuticals Web Site.

Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist.
Stroke 2000 Feb;31(2):347-354

Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators.
J Neurosurg 1999 Nov;91(5):737-43

Termination of Acute Stroke Studies Involving Selfotel Treatment. ASSIST Steering Committee.
Lancet 1997 Jan 4;349(9044):32

Cerestat and other NMDA antagonists in ischemic stroke.
Neurology 1997 Nov;49(5) Suppl 4):S66-S69.

UID: 10